Has anyone here ever dealt with paratoid gland squamous cell cancer? Post surgical paratoidectomy followed by radiation and still searching for answers to cure. Any positive results with other options tried? Thanks@
Interested in more discussions like this? Go to the Head and Neck Cancers group.
surfertam,
I'm Carol, a moderator here. I'm sure you've been told that parotid gland squamous cell cancer is rare. Also 80% of parotid gland tumors are benign. When something is that rare it can be difficult to access recent reliable sourced literature about it. I'm a retired RN with oncology and hospice being the fields I practiced in. I've not had a patient with parotid gland SCC, so I'm answering with what I just read about the disease and treatment. A little more information would be helpful. How old are you? How many neck nodes were involved? What's the doctor's plan for treatment?
Carol
Hi Surfertam,
I've been diagnosed Malign Carsinoma (no subdivision) of parotid gland 3.5 years ago. I had surgery of outer part of the gland and a couple of LN without touching the facial nerve. Had following 33 RT and 3 chemo and radiation totaly removed deeper part of the gland. Now I'm cancer free 3.5 years with slight side effects of surgery and radiation only. Since the type of tumor was not the regular one this gland, I was a bid lucky. Hope above helps.
Did the doctors do genomic testing on the cancer to see if might respond to some of newer precison immunotherpay treatments? http://news.cancerconnect.com/types-of-cancer/head-and-neck-cancers/salivary-gland-cancer/early-stage-iii-salivary-gland-cancer/
what stage is the cancer?
larotrectinib (LOXO-101) data just released and this new precision cancer medicine looks to benefit some with salivary gland cancers: Larotrectinib Demonstrates 76 Percent Response Rate in TRK Fusion Cancers Including Those of the Salivary Gland
http://news.cancerconnect.com/larotrectinib-demonstrates-76-percent-response-rate-trk-fusion-cancers-including-salivary-gland/
This landmark approval represents the first targeted therapy approved for a histology-agnostic indication